Foros de Conocimiento
medtronic PRODUCTOS
boston_scientific PRODUCTOS
TERUMO PRODUCTOS
Biotronik PRODUCTOS
Sirtex PRODUCTOS
Striker Neurovascular PRODUCTOS
BIOSENSORS PRODUCTOS

ESTUDIOS


01 septiembre 2013

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY.

S. Thomis, P. Verbrugghe, R. Milleret, E. Verbeken, I. Fourneau, P. Herijgers

Objective: There is an increasing use of minimal invasive techniques to treat saphenous vein reflux. Among these radiofrequency ablation (RFA), endovenous laser ablation (EVLA), and foam sclerotherapy are frequently used. A new method of thermal ablation is the steam vein sclerosing (SVS) system. This study evaluates the histological changes after ablation of the saphenous veins in goats with RFA, EVLA, and SVS.

01 octubre 2014

ENDOVASCULAR TODAY. TVR Reduction in the SFA

By Koen Deloose, MD; Marc Bosiers, MD; and Joren Callaert, MD

Although endovascular techniques have markedly improved over the past decades, the important rates of restenosis and the frequent need for target vessel revascularization (TVR) remain challenging when nominating any endovascular approach as the gold standard technique. Particularly in areas as difficult as the femoropopliteal tract, long-term procedural success is hindered by extensive plaque burden, as well as numerous external mechanical stressors. Long (TASC II C and D), severely calcified (grade 3–4, > 270° calcium) lesions in the distal femoropopliteal segment in patients with critical limb ischemia with multilevel disease and significant runoff still have high TVR rates.

01 octubre 2014

ENDOVASCULAR TODAY. Managing Perforations of the Superficial Femoral Artery

By Warren Swee, MD, MPH; Jeffrey Y. Wang, MD; and Arthur C. Lee, MD

Perforations along the superficial femoral artery (SFA) can occur from a variety of causes; if unrecognized or mismanaged, they can result in significant morbidity and even mortality. In the worst cases, uncontrolled bleeding can lead to hemodynamic instability and the need for open surgical management, blood transfusions, and prolonged hospital stays. From a procedural standpoint, perforations can result in prolonged procedure times, incomplete treatment, and tremendous frustration to the operator. This article focuses on SFA perforations related to endovascular interventions, although many of the treatment methods can be applied to other causes of perforation, such as penetrating trauma or crush injury. The prevention of perforations will be discussed first, because the best way to manage any complication is to avoid it altogether. Then, common mechanisms of perforation and the most effective treatment options will be reviewed (see Common Procedure-Related Causes of SFA Perforations and Techniques to Treat SFA Segment Perforations).

01 octubre 2014

ENDOVASCULAR TODAY. Acute Arterial Thrombosis Prevention and Management During SFA and Popliteal Interventions

By George L. Adams, MD, MHS, and O Jesse Mendes, BA

Acute arterial thrombosis can cause myocardial infarction (MI), ischemic stroke, and acute limb ischemia (ALI). The annual incidences of such events are high; there were 935,000 MI and 795,000 stroke events in the United States in 2008.1 However, the incidence and prevalence of acute peripheral arterial thrombosis is not well described, even in lieu of its devastating consequences, including morbidity, mortality, and limb loss.1,2

01 octubre 2014

ENDOVASCULAR TODAY. Distal Embolization in Femoropopliteal Interventions

By Nicolas W. Shammas, MD, MS, FACC, FSCAI

Distal embolization (DE) occurs frequently during femoropopliteal (FP) interventions. Treatment of FP atherosclerotic lesions with balloon angioplasty, stenting, atherectomy, embolectomy, or catheter-directed lysis is likely to yield significant debris.1-11 Despite a high rate of DE reaching 100% in some reports,3,10 data suggest that only 2% to 3% of patients will eventually require additional pharmacological and/or mechanical treatment.12

01 octubre 2014

ENDOVASCULAR TODAY. Strategies for Femoropopliteal In-Stent Restenosis

By Ehrin J. Armstrong, MD, MSc

Despite advances in endovascular therapy, femoropopliteal in-stent restenosis (FP-ISR) remains a frequent clinical challenge. It is estimated that approximately 115,000 cases of FP-ISR occur each year in the United States.1 Therefore, identifying optimal treatments for FP-ISR is critical for improving the outcomes of endovascular therapy. This article reviews the safety and efficacy of current treatment options for FP-ISR, including balloon angioplasty, laser atherectomy with adjunctive balloon angioplasty, drug-eluting stents, and emerging uses of drug-coated balloons (DCBs).

01 octubre 2014

ENDOVASCULAR TODAY. When would you elect to use a DCB versus a DES for SFA interventions, and what guides your decision making?

With Francesco Liistro, MD; Sebastian Sixt, MD; Gary Ansel, MD; and Marianne Brodmann, MD

Although the drug-coated balloon (DCB) was initially thought to be an alternative to stenting in superficial femoral artery (SFA) interventions, it is our opinion that the DCB will never walk alone, as the limitations of this technology (in particular, the lack of mechanical scaffolding and uncertainties regarding adequate drug delivery to complex, calcified lesions) prevent its solo use in several cases.

01 octubre 2014

ENDOVASCULAR TODAY. Factors Affecting Reduction in SFA Stent Fracture Rates

By Martin Werner, MD

The superficial femoral artery (SFA) is highly exposed to biomechanical forces occurring during leg movement. The superficial course of the artery, with crossing of flexion points as well as interaction with the surrounding musculature, exposes the artery to external forces, including compression, torsion, and elongation.1 The implantation of metallic stents is standard for the treatment of SFA atherosclerotic disease; however, concerns exist about the potential for nitinol stents to fracture and the clinical implications of these stent fractures.1 Some reports suggest that stent fractures are associated with a higher incidence of in-stent restenosis, thrombosis, or embolism.2-4 Others do not report a significant association between stent fracture and clinical deterioration.5,6-8

01 octubre 2014

ENDOVASCULAR TODAY. Optimizing PAD Treatment With the Phoenix Atherectomy System

By Stephen B. Williams, MD, MPH

More than 19 million Americans now suffer from peripheral artery disease (PAD),1,2 and, correspondingly, the economic cost of this disease is becoming increasingly overwhelming. It is now estimated that the annual economic burden from PAD is between $160 and $290 billion.3,4

01 noviembre 2013

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY. Worse Limb Prognosis for Indirect versus Direct Endovascular Revascularization only in Patients with Critical Limb Ischemia Complicated with Wound Infection and Diabetes Mellitus

O. Iida , M. Takahara , Y. Soga , Y. Yamauchi , K. Hirano , J. Tazaki , T. Yamaoka , N. Suematsu , K. Suzuki , Y. Shintani , Y. Miyashita , M. Uematsu

To investigate factors in patients with critical limb ischemia (CLI) and isolated infrapopliteal lesions that adversely affect outcomes of endovascular therapy (EVT) with or without angiosome-oriented revascularization.

01 octubre 2013

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY. Quantitative Evaluation of the Outcomes of Revascularization Procedures for Peripheral Arterial Disease Using Indocyanine Green Angiography

K. Igari , T. Kudo , T. Toyofuku , M. Jibiki , Y. Inoue , T. Kawano

We performed indocyanine green angiography (ICGA) in patients with peripheral arterial disease (PAD), and established a method for the quantitative measurement of appropriate parameters to assess peripheral perfusion and the applicability of ICGA tests.

Utilizamos cookies propias para el correcto funcionamiento del sitio web y mejorar nuestros servicios. Pulse el botón Aceptar todas para aceptar su uso. Puede cambiar la configuración u obtener más información en nuestra Política de cookies o pulsando Modificar configuración.